

## SUPPLEMENTARY FIGURES

Outcome	Dapagliflozin		Placebo	
	No/total no (%)	Events/100 patient-year	No/total no (%)	Events/100 patient-year
<b>Primary outcome</b>				
<b>Primary composite outcome</b>	197/2152 (9.2)	4.6	312/2152 (14.5)	7.5
Decline in eGFR of >50%	112/2152 (5.2)	2.6	201/2152 (9.3)	4.8
<b>End stage kidney disease</b>	109/2152 (5.1)	2.5	161/2152 (7.5)	3.8
eGFR <15 mL/min/1.73m <sup>2</sup>	84/2152 (3.9)	1.9	120/2152 (5.6)	2.8
Long term dialysis	68/2152 (3.2)	1.5	99/2152 (4.6)	2.2
Kidney transplantation	3/2152 (0.1)	0.1	8/2152 (0.4)	0.2

State	Dapagliflozin	Placebo	Total	%
CKD stage 5	84	120	204	53.4
Dialysis	68	99	167	43.72
Transplantation	3	8	11	2.88

$$\text{ESKD cost} = (53.4\% \times \text{CKD stage 5 cost}) + (43.7\% \times \text{dialysis cost}) + (2.8\% \times \text{transplantation cost})$$

### Figure S1: Derivation of event cost associated with ESKD

ESKD costs were calculated on a weighted aggregate of CKD stage 5, dialysis and transplantation based on distribution from the DAPA-CKD trial.[1] eGFR: estimated glomerular filtration rate; ESKD: end-stage kidney disease.

## SUPPLEMENTARY TABLES

**Table S1: List of countries included in the analysis**

*International Organization for Standardization (ISO) country codes.*

<b>Country Abbreviation</b>	<b>Full Name</b>
ARE	United Arab Emirates
AUS	Australia
BEL	Belgium
BRA	Brazil
CAN	Canada
CHN	China
COL	Columbia
DEU	Germany
DNK	Denmark
ESP	Spain
FRA	France
GBR	United Kingdom
GRC	Greece
HUN	Hungary
IND	India
ISR	Israel
ITA	Italy
JPN	Japan
KOR	South Korea
MEX	Mexico
NLD	Netherlands
PHL	Philippines
POL	Poland
ROU	Romania
SAU	Saudi Arabia
SGP	Singapore
SWE	Sweden
THA	Thailand
TUR	Turkey
TWN	Taiwan
USA	United States of America

**Table S2. Cumulative costs (thousands) associated to clinical outcomes across 31 countries/regions over three years, 2022 USD**

Outcome	ESKD			HHF			AKI			Total		
Country	DAPA + ST	ST	Costs avoided	DAPA + ST	ST	Costs avoided	DAPA + ST	ST	Costs avoided	DAPA + ST	ST	Costs avoided
Australia	\$609,622	\$901,859	-\$292,238	\$30,671	\$60,624	-\$29,953	\$32,101	\$45,457	-\$13,356	\$672,393	\$1,007,940	-\$335,547
Belgium	\$878,096	\$1,298,827	-\$420,731	\$42,671	\$84,345	-\$41,673	\$150,079	\$212,521	-\$62,441	\$1,070,847	\$1,595,692	-\$524,846
Brazil	\$135,479	\$200,492	-\$65,013	\$6,751	\$13,345	-\$6,594	\$3,875	\$5,487	-\$1,612	\$146,106	\$219,324	-\$73,218
Canada	\$600,433	\$888,560	-\$288,128	\$24,049	\$47,535	-\$23,486	\$40,080	\$56,755	-\$16,675	\$664,561	\$992,850	-\$328,289
China	\$221,694	\$328,081	-\$106,386	\$18,764	\$37,089	-\$18,325	\$24,999	\$35,401	-\$10,401	\$265,458	\$400,570	-\$135,113
Colombia	\$215,125	\$318,211	-\$103,086	\$11,588	\$22,905	-\$11,317	\$31,182	\$44,156	-\$12,974	\$257,895	\$385,271	-\$127,376
Denmark	\$565,702	\$836,615	-\$270,913	\$12,399	\$24,508	-\$12,109	\$20,141	\$28,521	-\$8,380	\$598,242	\$889,644	-\$291,402
France	\$1,140,208	\$1,686,495	-\$546,287	\$26,570	\$52,519	-\$25,949	\$97,560	\$138,150	-\$40,590	\$1,264,338	\$1,877,164	-\$612,826
Germany	\$854,067	\$1,263,579	-\$409,512	\$12,498	\$24,704	-\$12,206	\$11,048	\$15,645	-\$4,597	\$877,614	\$1,303,928	-\$426,314
Greece	\$639,771	\$946,172	-\$306,401	\$19,871	\$39,278	-\$19,406	\$8,541	\$12,095	-\$3,554	\$668,183	\$997,544	-\$329,361
Hungary	\$253,809	\$375,411	-\$121,602	\$363	\$718	-\$355	\$9,639	\$13,649	-\$4,010	\$263,812	\$389,779	-\$125,967
India	\$55,973	\$82,938	-\$26,966	\$8,698	\$17,192	-\$8,494	\$8,099	\$11,468	-\$3,370	\$72,769	\$111,599	-\$38,830
Israel	\$733,769	\$1,085,709	-\$351,941	\$12,498	\$24,704	-\$12,206	\$19,964	\$28,270	-\$8,306	\$766,231	\$1,138,683	-\$372,453
Italy	\$476,409	\$704,799	-\$228,390	\$46,371	\$91,658	-\$45,287	\$23,209	\$32,865	-\$9,656	\$545,989	\$829,321	-\$283,333
Japan	\$430,487	\$636,823	-\$206,336	\$20,858	\$41,229	-\$20,370	\$874	\$1,238	-\$364	\$452,220	\$679,290	-\$227,070
Mexico	\$156,327	\$231,573	-\$75,247	\$23,101	\$45,661	-\$22,560	\$4,455	\$6,308	-\$1,853	\$183,882	\$283,543	-\$99,661
Netherlands	\$1,133,143	\$1,675,723	-\$542,580	\$20,523	\$40,566	-\$20,043	\$29,519	\$41,800	-\$12,281	\$1,183,185	\$1,758,089	-\$574,904
Philippines	\$211,169	\$312,489	-\$101,320	\$10,477	\$20,709	-\$10,232	\$3,987	\$5,646	-\$1,659	\$225,633	\$338,844	-\$113,211
Poland	\$323,233	\$477,993	-\$154,759	\$19,871	\$39,278	-\$19,406	\$10,363	\$14,675	-\$4,312	\$353,467	\$531,945	-\$178,477
Romania	\$449,213	\$664,469	-\$215,256	\$6,846	\$13,533	-\$6,686	\$22,783	\$32,262	-\$9,479	\$478,843	\$710,264	-\$231,421
Saudi Arabia	\$342,493	\$506,989	-\$164,496	\$26,954	\$53,278	-\$26,324	\$25,110	\$35,557	-\$10,447	\$394,558	\$595,825	-\$201,267
Singapore	\$352,352	\$521,410	-\$169,058	\$20,613	\$40,744	-\$20,131	\$13,819	\$19,569	-\$5,750	\$386,785	\$581,723	-\$194,938
South Korea	\$420,260	\$621,863	-\$201,603	\$884	\$1,747	-\$863	\$13,819	\$19,569	-\$5,750	\$434,963	\$643,178	-\$208,215
Spain	\$730,608	\$1,080,568	-\$349,959	\$28,406	\$56,148	-\$27,742	\$29,235	\$41,398	-\$12,163	\$788,249	\$1,178,114	-\$389,865
Sweden	\$943,257	\$1,395,145	-\$451,887	\$21,494	\$42,485	-\$20,991	\$18,238	\$25,826	-\$7,588	\$982,989	\$1,463,456	-\$480,467
Taiwan	\$240,513	\$355,887	-\$115,374	\$1,674	\$3,308	-\$1,634	\$1,229	\$1,740	-\$511	\$243,416	\$360,935	-\$117,519

<b>Outcome</b>	<b>ESKD</b>			<b>HHF</b>			<b>AKI</b>			<b>Total</b>		
<b>Country</b>	<b>DAPA + ST</b>	<b>ST</b>	<b>Costs avoided</b>	<b>DAPA + ST</b>	<b>ST</b>	<b>Costs avoided</b>	<b>DAPA + ST</b>	<b>ST</b>	<b>Costs avoided</b>	<b>DAPA + ST</b>	<b>ST</b>	<b>Costs avoided</b>
Thailand	\$217,903	\$322,460	-\$104,557	\$8,698	\$17,192	-\$8,494	\$6,015	\$8,517	-\$2,502	\$232,615	\$348,169	-\$115,554
Turkey	\$210,622	\$311,624	-\$101,002	\$5,234	\$10,346	-\$5,112	\$6,110	\$8,652	-\$2,542	\$221,966	\$330,621	-\$108,655
UAE	\$479,615	\$707,914	-\$228,299	\$46,371	\$91,658	-\$45,287	\$25,110	\$35,557	-\$10,447	\$551,096	\$835,128	-\$284,033
UK	\$309,287	\$457,462	-\$148,175	\$10,759	\$21,267	-\$10,508	\$14,729	\$20,857	-\$6,128	\$334,775	\$499,586	-\$164,811
USA	\$895,175	\$1,324,318	-\$429,143	\$57,384	\$113,425	-\$56,042	\$34,675	\$49,102	-\$14,427	\$987,235	\$1,486,846	-\$499,612

AKI: acute kidney injury; DAPA: dapagliflozin; HHF: hospitalization for heart failure; ST: standard therapy; UAE: United Arab Emirates; UK: United Kingdom; USA: United States of America

**Table S3: Inside CKD Scientific Steering Committee**

<b>Country/region</b>	<b>Key external expert</b>	<b>Affiliation</b>
Australia	Prof. Steven Chadban	Royal Prince Alfred Hospital, Sydney, Australia
Belgium	Prof. Michel Jadoul	Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
Brazil	Prof. Marcelo Costa Batista	Hospital Israelita Albert Einstein, São Paulo, Brazil
Canada	Dr Navdeep Tangri	University of Manitoba, Winnipeg, Canada
China	Prof. Guisen Li	Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu, China
Colombia	Prof. José Javier Arango Álvarez	Universidad del Quindío, Quindío, Colombia
Denmark	Professor Christian Fynbo Christiansen	Aarhus University Hospital, Denmark
France	Prof. Jean-Michel Halimi	Service de Néphrologie-HTA, Dialyses, Transplantation Rénale, CHU Tours, Tours, France
Germany	Prof. Kai-Uwe Eckardt	Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany
Greece	Dr Panos Stafylas	University of Macedonia
Hungary	Prof. Istvan Wittmann	President of Hungarian Diabetes Society and Hungarian College of nephrologists and Head of the Internal Medicine Department II. University of Pécs.
India	Prof. Vivekanand Jha	George Institute for Global Health India, New Delhi, India
Israel	Prof. Avraham Karasik	Maccabi Institute for Research and Innovation, Tel-Aviv, Israel
Israel	Prof. Gil Chernin	Kaplan Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
Italy	Prof. Francesco Saverio Mennini	CEIS-EEHTA, Faculty of Economics, University of Rome Tor Vergata, Rome, Italy
Italy	Prof. Luca De Nicola	Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy
Japan	Prof. Eiichiro Kanda	Kawasaki Medical University, Okayama, Japan
Mexico	Prof. José Ricardo Correa-Rotter	Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City, Mexico
Netherlands	Dr Chris Hagen	Meander Medical Centre
Philippines, Singapore, and Thailand	Assoc. Prof. Jason Choo Chon Jun	Singapore General Hospital, Singapore
Poland	Prof. Michał Nowicki	Warsaw University of Technology
Romania	Prof. Dr. Ismail Gener	Fundeni Institute
Saudi Arabia	Prof. Saeed M. G. Al-Ghamdi	King Abdulaziz University Hospital and King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
South Korea	Prof. Kook-Hwan Oh	Seoul National University College of Medicine, Seoul, South Korea
Spain	Prof. Juan Francisco Navarro-González	Research Unit and Nephrology Service, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
Sweden	Prof. Johan Ärnlöv	Department of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institute, Stockholm, Sweden
Taiwan	Prof. Mai-Szu Wu	Division of Nephrology, Taipei Medical University, Taipei, Taiwan

<b>Country/region</b>	<b>Key external expert</b>	<b>Affiliation</b>
Turkey	Prof. Mustafa ARICI	Hacettepe University Faculty of Medicine, Department of Nephrology, Ankara, Turkey
United Arab Emirates	Prof. Stephen Holt	SEHA Kidney Care, Abu Dhabi, UAE
United Kingdom	Dr Albert Power	North Bristol NHS Trust, Bristol, UK
United States of America	Prof. Glenn Chertow	Stanford University School of Medicine, California, USA
United States of America	Prof. Jay Wish	Indiana University School of Medicine, Indianapolis, USA

## REFERENCES

1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. *New England Journal of Medicine*. 2020;383(15):1436-1446.